Please assess the completion status of the following clinical trial:

Trial Title: Vaccination Adjuved Against Hepatitis B in SNS Workers Typed as no Responders to Conventional Vaccines

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* NHS workers -including university students doing their internships in health centres dependent on the National Health System (inclusion of students is regulated and limited by specific instructions on labour prevention in each autonomous community).~* Criteria defining them as NO responders to the conventional hepatitis B vaccine: anti HBsAb titers \<10 mIU / ml following the application of six doses of conventional vaccine at 20 μg doses (two complete guidelines).~Exclusion Criteria:~* Known allergy to the active substance or any of the other ingredients of the medicinal product (included in section 6 of the product data sheet).~* Subjects that have ever had an allergic reaction to any vaccine against hepatitis B.~* Subjects have a serious infection with fever.~* Subjects for whom informed consent is not obtained.~* Subjects that have not revoked the consent initially signed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Fendrix (Type: EXPERIMENTAL): The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).